GSK, Vir Say U.S. to Buy Added Supply of Covid Treatment

By Michael Dabaie

GlaxoSmithKline PLC and Vir Biotechnology Inc. said the U.S. government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of Covid-19.

The companies said the additional 600,000 doses would be delivered throughout the first quarter of 2022. The agreement is an amendment to earlier commitments unveiled with the U.S. government in November 2021.

GSK and Vir said they have received binding agreements for the sale of about 1.7 million doses of sotrovimab worldwide.

Tuesday's agreement also includes the option for the U.S. government to purchase further additional doses in the second quarter of 2022.

Sotrovimab, which was granted emergency use authorization by the U.S. Food and Drug Administration in May, is an investigational single-dose intravenous infusion SARS-CoV-2 monoclonal antibody.

Under the EUA, sotrovimab can be used for the treatment of mild-to-moderate Covid-19 in adults and pediatric patients 12 and older.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

January 11, 2022 07:55 ET (12:55 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.